After an AML diagnosis, Joseph joined a clinical trial that matched his disease. Today, he’s with family, coaching young riders, and riding again. His story shows how research expands options and moves cancer care forward. 🔗 www.scri.com/patients/jos... #EveryClinicalTrialTellsAStory #SCRI

Every dot represents a patient—and a step forward. SCRI’s growing national footprint is expanding access to clinical trials, bringing research closer to more patients through collaboration across our sites.

Meet Katelyn, a SCRI clinical trial participant through SCRI Oncology Partners. After stage 3 ER+/HER2- breast cancer, she enrolled in a trial and now has no evidence of disease—recently completing her 50th state in Alaska. Read her story: 🔗Read Katelyn’s Story #SCRI #PatientStories #HopeInAction

Today, we celebrate survivors—and the strength behind every story. 💙 National Cancer Survivor’s Day is a reminder of what’s possible with courage, compassionate care, and progress in research. Today- and every day - we celebrate you. #NationalCancerSurvivorsDay #CancerSurvivor #HopeInAction #SCRI

Meet Jim, who chose a clinical trial as his first step in treatment—close to home through SCRI and SCRI Oncology Partners. His story highlights how trials can be an active, empowering choice in care. 🔗 Read more at the link in bio #EveryClinicalTrialTellsAStory #SCRI

Wrapping up strong at #ASCO26 with SCRI Meet the Expert sessions in GI, breast, and innovation in trial delivery through Accelero. Come connect with our teams!

Tomorrow is the final day at #ASCO26 and we're ending strong! Dr. Erika Hamilton presents on HER2-targeted combination therapy in metastatic breast cancer. #InnovationInCancerCare #SCRI #ASCO26 www.scri.com/asco/

ASCO

Our accelerated operations model, Accelero maximizes all parts of SCRI to accelerate drug development and optimize clinical trial delivery. Coordinated through our CRO, SCRI Development Innovations, Accelero enhances connectivity to SCRI research sites, which in turn maximizes site contributions, optimizes site activation timelines, and synchronizes end-to-end clinical research management. Learn more.

scri.com

Meet SCRI experts at #ASCO26 for a lymphoma session led by Krish Patel MD. Join the conversation and learn how we are advancing research for patients.

Tomorrow is Day 4 at #ASCO26. Catch SCRI experts leading key sessions and sharing insights on advancing cancer care in community settings. From trial innovation to real-world impact, we’re proud to help shape what’s next in oncology.

Tomorrow is Day 3 at #ASCO26. Catch SCRI experts presenting the latest research in hematologic cancers and solid tumors, including Dr. Melissa Johnson, Dr. Peter Forsberg, Dr. Debra Patt, Dr. Elisa Fontana and Dr. James Essell.

Join SCRI at #ASCO26 for Meet the Expert sessions on head and neck cancer, myeloma, leukemia and melanoma. Connect with our investigators at booth 22035.

We look forward to seeing more of you on day two of the Annual #ASCO26 Meeting. Stop by both #22035 to meet our scientific leaders. www.scri.com/asco

At #ASCO26, join us for Conquering Veteran Cancer, Together — Sun, May 31 | 9:30–11:30 a.m. CT at Hyatt Regency. Proud our CEO Dee Anna Smith is speaking. Register: bmsmeetings.cventevents.com/gqmKoN

Day 1 of #ASCO26 is here. Our experts are presenting the latest research in hematologic disorders & more. Dr. Hans Lee will share first results from the Phase 1/2 LINKER-AL2 trial. #SCRI #OncologyLeadership #CancerResearch

SCRI is advancing cancer research through community-based clinical trials and decades of innovation. Explore our latest insights from #ASCO26: www.scri.com/asco

Some stories are measured in decades. 💙 20 years ago, Lisa joined a clinical trial through @texasoncology.bsky.social & SCRI—just after having her first child. Today, Lisa is thriving & that child is in college. 🔗 Read her story: link in bio #EveryClinicalTrialTellsAStory

Clinical trials are key to advancing cancer care—and understanding them can open new possibilities. This #ClinicalTrialsDay, we’re sharing 5 things to know about trials and how they may support your care journey. 🔗 Learn more: scri.com/patients/faqs #SCRI

SCRI announces a strategic oncology collaboration w/ Pfizer to accelerate clinical trials and expand patient access to promising therapies—marking #ClinicalTrialsDay and advancing research w/ our Accelero™ model, delivering trials faster, closer to home. www.scri.com/news/sarah-c...

Two relapses. A new path forward. After Waldenström macroglobulinemia returned twice, Carol joined an SCRI clinical trial at Colorado Blood Cancer Institute. More than a year later, she’s doing well—and back to what she loves. Read her story: scri.com/patients/carol

Meredith Pelster, MD, SCRI Oncology Partners serves as a contributing author on a @nejm.org publication on daraxonrasib in previously treated RAS‑mutated pancreatic cancer. Important progress for pancreatic cancer research. Article: nejm.org/doi/10.1056/... #NEJM #PancreaticCancer

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM

Current therapies for patients with pancreatic ductal adenocarcinoma (PDAC) provide modest benefit. Activating RAS mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an ora...

nejm.org

Meet JP, a patient who participated in a clinical trial close to home at Oncology Hematology Care (OHC) through SCRI. His story highlights the importance of trust, access, & community based research—where patients are supported every step of the way. 🔗 www.scri.com/patients/jp/

New in NEJM: Phase 1 data on setigrasib, a first‑in‑class #KRAS G12D degrader, showed encouraging early activity in NSCLC and #PancreaticCancer, with a manageable safety profile. Proud to see #SCRI's Drs. Pelster & Wang contribute to this study. www.nejm.org/doi/full/10....

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer | NEJM

The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patient...

nejm.org

On #DoctorsDay, we celebrate the physicians across #SCRI who are driving innovation, advancing clinical research, and putting patients first every day. Your leadership, curiosity, and commitment are shaping the future of cancer care. Thank you for all you do. #PhysicianLeadership #ClinicalTrials

🧬 Dr. Benjamin Garmezy discusses emerging prostate cancer strategies—highlighting molecular glues & T‑cell engagers—in a new CancerNetwork interview. 🔗 www.cancernetwork.com/view/emergin... #ProstateCancer #Oncology #PrecisionMedicine #SCRI

Emerging Strategies in Prostate Cancer: Molecular Glues and T-Cell Engagers | CancerNetwork

Benjamin Garmezy, MD, discussed the potential of a GSPT1 molecular glue degrader and a trispecific T-cell engager in treating select prostate cancers.

cancernetwork.com

Dr. Meredith Pelster of #SCRIOncologyPartners joined #NewsChannel5’s Let Me Help to discuss colorectal cancer and the importance of early screening. 👏 Watch the segment: www.newschannel5.com/news/let-me-...

Let Me Help: Learning more about colorectal cancer

March is Colorectal Cancer Awareness Month. Colorectal cancer is now the number one cause of cancer death in adults under 50, with cases rising 1% annually in this group.

newschannel5.com

In a new Scrip Asks, SCRI’s David Spigel, MD, discusses what 2026 holds for biopharma in oncology R&D and the push to operationalize complex therapies. insights.citeline.com/scrip/scrip-... #Oncology #Biopharma #RAndD #CancerResearch #ClinicalResearch #Innovation

Scrip Asks... What Does 2026 Hold For Biopharma? Part 4: R&D Innovation

Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological a...

insights.citeline.com

As SCRI enters a new chapter, Drs. Spigel, Johnson, Hamilton & Subbiah share how scientific momentum is making community‑based research more important than ever. www.ajmc.com/view/as-new-... #ClinicalResearch

As New Leaders Rise at SCRI, the Mission Remains: Bringing Clinical Trials Where Patients Live | AJMC

New leaders of the Sarah Cannon Research Institute discuss its mission and priorities amid a changing landscape in community oncology.

ajmc.com

SCRI and SCRI Oncology expert, Dr. Meredith Pelster joined Pharmacy Times to discuss emerging data that could meaningfully change the treatment landscape for pancreatic cancer. Watch below to learn more: www.pharmacytimes.com/view/atebime... #PancreaticCancer #SCRI #OncologyResearch

Atebimetinib Signals a Potential Shift in First-Line Pancreatic Cancer Outcomes | Pharmacy Times

Experts discuss groundbreaking data on pancreatic cancer treatment, revealing a 64% survival rate and its potential to transform patient care and outcomes.

pharmacytimes.com

Dr. Erika Hamilton, #SCRI's CDO of Late Phase, as well as Director of Breast Cancer Research, sat down with CURE Today to discuss thenHER2CLIMB-05 trial. Read how this trial is making waves for people facing HER2-positive metastatic breast cancer. www.curetoday.com/view/tukysa-...

Tukysa Makes Waves as Firstline Maintenance in HER2+ Breast Cancer | CURE

Dr. Erika Hamilton sat down for an interview with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

curetoday.com

AI is revolutionizing cancer care. Dr. David Spigel, President & CMO at Sarah Cannon Research Institute, shares how personalized treatments and clinical trials are evolving. Read the NewsChannel5 feature: www.newschannel5.com/news/let-me-... #CancerResearch #AIinHealthcare

Let Me Help: Can AI personalize my cancer treatment

Dr. David Spigel is a medical oncologist at SCRI Oncology Partners in Nashville and President and Chief Medical Officer for Sarah Cannon Research Institute.

newschannel5.com